Compare NMRK & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMRK | HTFL |
|---|---|---|
| Founded | 1929 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2017 | 2025 |
| Metric | NMRK | HTFL |
|---|---|---|
| Price | $15.25 | $42.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $18.75 | ★ $38.20 |
| AVG Volume (30 Days) | ★ 1.4M | 948.3K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 100.00 | 82.37 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $3,294,024,000.00 | $176,034,000.00 |
| Revenue This Year | $12.45 | $27.66 |
| Revenue Next Year | $8.02 | $23.55 |
| P/E Ratio | $85.00 | ★ N/A |
| Revenue Growth | 20.29 | ★ 39.92 |
| 52 Week Low | $13.36 | $20.13 |
| 52 Week High | $19.84 | $41.22 |
| Indicator | NMRK | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 83.53 |
| Support Level | $14.95 | $24.59 |
| Resistance Level | $16.05 | N/A |
| Average True Range (ATR) | 0.57 | 1.81 |
| MACD | -0.02 | 1.42 |
| Stochastic Oscillator | 51.56 | 94.88 |
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.